Company Overview

HAVN Life Sciences Inc. is a Canadian biotechnology and consumer packaged goods company focused on the research, development, and commercialization of psychedelic compounds, functional mushrooms, and natural health products. The company has operated at the intersection of the mental health, wellness, and biotechnology sectors, with an emphasis on developing standardized formulations and evidence-based products derived from psychoactive and non-psychoactive fungi. Its activities have included both scientific research initiatives and direct-to-consumer wellness product offerings.

The company’s primary revenue drivers have historically included sales of natural health and wellness products, alongside intellectual property development and research activities tied to psychedelic science. HAVN Life Sciences positioned itself as an early participant in the emerging psychedelic wellness market in North America, particularly during the expansion of investor and clinical interest in psilocybin-related therapies. Public disclosures and market filings indicate that the company evolved from a wellness-focused product platform into a broader life sciences organization seeking exposure to mental health therapeutics and nutraceutical innovation.

Business Operations

HAVN Life Sciences has operated through activities associated with product development, scientific research, and wellness branding. Its business model included the commercialization of mushroom-derived products and nutraceutical formulations while also pursuing research partnerships and laboratory capabilities related to psychedelic compounds. The company’s operations were primarily centered in Canada, with commercial and investor-facing activities extending into the United States wellness market.

The company has referenced laboratory and formulation capabilities associated with psychedelic and functional mushroom research, including intellectual property development and standardized extraction processes. Public information indicates involvement with branded wellness product lines and research-driven initiatives intended to support future therapeutic applications. Data regarding large-scale international subsidiaries, major joint ventures, or long-term commercial manufacturing infrastructure remains limited in publicly available disclosures, and certain operational details are inconclusive based on available public sources.

Strategic Position & Investments

HAVN Life Sciences pursued a strategy focused on participating in the growing psychedelic health and wellness industry through a combination of consumer wellness products and early-stage scientific development. Its strategic direction emphasized functional mushrooms, mental wellness solutions, and the exploration of psilocybin-related research opportunities as regulatory frameworks evolved in Canada and internationally. The company also sought to establish brand recognition within the broader natural health and alternative therapeutics market.

The company has publicly discussed investments in research capabilities, product formulation, and intellectual property associated with psychedelic sciences and nutraceutical applications. Strategic initiatives included expanding product distribution channels and participating in the broader ecosystem of mental health innovation companies. However, publicly verified information regarding major acquisitions, material portfolio holdings, or large-scale strategic investments remains limited. Data inconclusive based on available public sources.

Geographic Footprint

HAVN Life Sciences has been headquartered in Canada, with operational and corporate activities primarily concentrated in British Columbia. The company’s public market presence extended into both the Canadian and U.S. investment communities through its public listings and investor communications. Commercial outreach and product marketing efforts also targeted consumers in North America, particularly within the wellness and natural health sectors.

While the company’s strategic messaging referenced opportunities in the global psychedelic and mental wellness market, verified operational infrastructure outside Canada and the United States has not been extensively documented in public filings. Its geographic footprint appears to have remained primarily North American, with limited publicly confirmed evidence of material operations across Europe, Asia, or other international regions.

Leadership & Governance

HAVN Life Sciences has been led by executives with backgrounds in biotechnology, wellness products, entrepreneurship, and public markets. Corporate leadership communications emphasized the integration of scientific research, consumer wellness, and emerging mental health therapies as part of the company’s long-term strategic vision. Governance and operational direction were communicated through public company filings, investor presentations, and corporate announcements.

Key executives and leadership figures publicly associated with the company have included:

• Tim Moore – Chief Executive Officer
• Vic Neufeld – Executive Chairman
• Jason Mitchell – Chief Operating Officer
• David Kideckel – Chief Financial Officer

Certain leadership roles and executive appointments may have changed over time based on subsequent corporate developments and public disclosures.